I received a couple of questions about one of my slides on a previous post. This is an early result from some work I’ve been doing with University College London Hospitals NHS Foundation Trust looking at how we can improve cure rates following radiotherapy for #lungcancer Here we’ve tried two different ways or reducing the radiation dose received […]
Nothing triggers my imposter syndrome more than planning post-operative radiotherapy for thymoma! As mentioned in a previous post, it really is an art – and like all art, it’s subjective. However, two key papers help reassure me. The work of Florit Marcuse highlights the importance of collaborative working, while Andreas Rimner‘s research shows that in experienced hands, post-operative […]
Thymomas are a rare cancer, but tend to occur in a younger age group, so the risks of secondary malignancy or radiation-associated heart disease need to be considered. My personal opinion is that proton beam therapy needs to be considered for every patient receiving adjuvant radiotherapy for thymoma.
Stereotactic Ablative Radiotherapy (SABR) is a cutting-edge treatment for lung cancer that delivers highly precise radiation therapy to tumours in the lungs. Unlike traditional radiation therapy, which may require numerous sessions, SABR delivers a concentrated dose of radiation in just a few sessions, often as few as one to five.
During SABR, advanced imaging techniques are used to precisely locate the tumour in the lung. The radiation beams are then carefully directed at the tumour from multiple angles, ensuring that the cancer cells receive a high dose of radiation while minimising exposure to surrounding healthy tissue.
SABR is an excellent option for patients with early-stage lung cancer who may not be candidates for surgery due to other medical issues. It offers a non-invasive alternative that can effectively destroy cancer cells while preserving lung function.